Immune-checkpoint inhibitors in melanoma and kidney cancer: from sequencing to rational selection

Immune-checkpoint inhibitors (ICPIs), including antibodies against cytotoxic T-lymphocyte associated antigen 4 and programmed cell death protein 1, have been shown to induce durable complete responses in a proportion of patients in the first-line and refractory setting in advanced melanoma and renal...

Descripción completa

Detalles Bibliográficos
Autores principales: Flynn, Michael, Pickering, Lisa, Larkin, James, Turajlic, Samra
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2018
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6024333/
https://www.ncbi.nlm.nih.gov/pubmed/29977349
http://dx.doi.org/10.1177/1758835918777427

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6024333/
https://www.ncbi.nlm.nih.gov/pubmed/29977349
http://dx.doi.org/10.1177/1758835918777427

Ejemplares similares